The Interaction Potential of Retigabine (Ezogabine) with Other Antiepileptic Drugs

ISSN: 2212-3938 (Online)
ISSN: 1574-8847 (Print)

Volume 12, 4 Issues, 2017

Download PDF Flyer

Current Clinical Pharmacology

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Arduino A. Mangoni
Flinders University and Flinders Medical Centre
Adelaide, SA

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

The Interaction Potential of Retigabine (Ezogabine) with Other Antiepileptic Drugs

Current Clinical Pharmacology, 9(2): 148-156.

Author(s): Debra J. Tompson and Christopher S Crean.

Affiliation: GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK.


Background: Retigabine is an antiepileptic drug (AED) that reduces neuronal excitability by enhancing neuronal KCNQ (Kv7) potassium channel activity.

Methods: This manuscript provides an overview of the drug-drug interaction potential of retigabine with other AEDs, using data collated from both in vitro work and clinical studies, either previously published or from relevant information collated during the development of retigabine.

Results: Retigabine is not a substrate for the major CYP enzymes and at clinically relevant concentrations there is little or no potential for retigabine to inhibit or induce the CYP enzymes or to inhibit the major renal drug transporters. The addition of retigabine to a range of existing AEDs showed little or no effect on the AED trough concentrations apart from a 20% decrease in lamotrigine concentrations. Results from a small phase II study showed that co-administration of valproic acid and topiramate had no impact on the PK of retigabine whereas carbamazepine and phenytoin increased the clearance of retigabine by approximately 27% and 36%, respectively. Conversely, a population PK analysis of combined data from phase I, II and III studies showed that none of the coadministered AEDs affected retigabine clearance apart from lamotrigine which lowered retigabine clearance by 6.7%.

Conclusion: Retigabine is not metabolized by CYP isozymes and does not induce or inhibit these isozymes at clinically relevant concentrations. Therefore, retigabine is associated with a low potential for PK interactions with other drugs via CYP450. Overall, there was little or no potential for retigabine to interact with other available AEDs. Although some PK interactions were observed with lamotrigine, these are unlikely to be clinically relevant.


Antiepileptic drug, drug-drug interactions, epilepsy, ezogabine, pharmacokinetics, retigabine.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 9
Issue Number: 2
First Page: 148
Last Page: 156
Page Count: 9
DOI: 10.2174/1574884708666131111192311
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science